Amerisource Bergen Corp.
ABC
Market Cap$36.39B
Close$
Earnings Call Q2 2023
May 2, 2023 - AI Summary
AmerisourceBergen reported strong financial performance in Q2 FY2023, with revenue growth of nearly 10% and adjusted EPS growth of 9%.
The company's pharmaceutical-centric strategy and leadership in specialty distribution continue to drive its success, with a focus on enhancing oncology-focused practice solutions and services.
AmerisourceBergen recently announced an investment in OneOncology, a network of community oncologists, to deepen its ties to community providers and expand its capabilities in inventory management, practice analytics, and clinical trial support.
Exclusive for Stockcircle Pro members
Sign up
$192.20
6.8% upside
Current Fair Value
6.8% upsideUndervalued by 6.8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $36.39 Billion |
|---|---|
| Enterprise Value | $40.02 Billion |
| Dividend Yield | $1.9304 (1.07%) |
| Earnings per Share | $8.19 |
| Beta | 0.4 |
| Outstanding Shares | 202,174,856 |
| Avg 30 Day Volume | 2,447,412 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 21.54 |
|---|---|
| PEG | 120.7 |
| Price to Sales | 0.14 |
| Price to Book Ratio | 59.99 |
| Enterprise Value to Revenue | 0.16 |
| Enterprise Value to EBIT | 15.08 |
| Enterprise Value to Net Income | 23 |
| Total Debt to Enterprise | 0.13 |
| Debt to Equity | 7.32 |
Revenue Sources
No data
ESG Score
No data
About Amerisource Bergen Corp.
22,000 employees
CEO: Steven Collis AmerisourceBergen provides pharmaceutical products, value-driving services and business solutions that improve access to care. Tens of thousands of healthcare providers, veterinary practices and livestock producers trust us as their part...